TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3115138
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20 mg tetracaine only)
Study: 28736918
Drug: Erenumab (AMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab (AMG 334), single doses ranging from 1 mg to 70 mg
Study: 28736918
Drug: Erenumab (AMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab (AMG 334), multiple doses
Study: 25832556
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding (n=44)
Study: 25832556
Drug: Late oral
Normalized name: Adalate Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late oral feeding (n=45)
Study: 24834772
Drug: SIT (Allergen-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT (Allergen-specific immunotherapy)
Study: 9355902
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (Control)
Study: 22808958
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (40 children)
Study: 2125547
Drug: Fluvoxamine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (starting at 50 mg for 3 days, increasing to 100 mg for 3 days, then up to 150 mg daily if necessary)
Study: 2125547
Drug: Imipramine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (starting at 50 mg for 3 days, increasing to 100 mg for 3 days, then up to 150 mg daily if necessary)
Study: 19190104
Drug: Continuous sc
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous sc insulin and pramlintide infusion (part B)
Study: 19190104
Drug: Continuous sc
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous sc insulin monotherapy (part A)
Study: 9726693
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dexibuprofen
Study: 9726693
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg dexibuprofen
Study: 9726693
Drug: Both dexibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both dexibuprofen preparations
Study: 30260294
Drug: JNJ-54175446 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-54175446 (doses ranging from 0.5 to 600 mg)
Study: 27455573
Drug: Remaxol (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remaxol (single daily intravenous administration, 400 mL at 3-4 mL/min rate) for 3-5 days after thrombolytic therapy
Study: 27455573
Drug: Conventional thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional thrombolytic therapy
Study: 25514391
Drug: Low glycemic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low glycemic index multi-nutrient supplement (breakfast replacement)
Study: 20123859
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention (before CPAP therapy)
Study: 20123859
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) therapy after 3 months
Study: 18590203
Drug: tijiaseluo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: tijiaseluo (6 mg, qd)
Study: 19589241
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg/day)
Study: 9589245
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 mg/day)
Study: 15716710
Drug: Combined (losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined (losartan 50 mg/day plus ramipril 5 mg/day)
Study: 15716710
Drug: Hydrochlorothiazide (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (12.5 mg/day) added as needed
Study: 8721801
Drug: Demographic variables
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demographic variables (e.g., being male, not having medical insurance)
Study: 8721801
Drug: Health beliefs
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health beliefs (e.g., extra beats are harmful, a higher degree of general health concern)
Study: 1918659
Drug: Lithium discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium discontinuation
Study: 1918659
Drug: Inositol administration
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol administration
Study: 7071805
Drug: Subcutaneous calcium
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous calcium heparin (5,000 units eight-hourly)
Study: 7071805
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin monitored by maintaining the standardised APTT at 50 secs
Study: 31215471
Drug: Surgical excision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical excision of the keloid scar followed by sub-dermal injection of triamcinolone acetonide (2 ampules of 10 mg/1 ml each) at the time of wound closure.
Study: 31215471
Drug: Surgical excision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical excision of the keloid scar without corticosteroid injection (control group).
Study: 23497336
Drug: Eltrombopag 75
Normalized name: eltrombopag 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 75 mg daily
Study: 8544782
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin infusion (5, 10, 20 mU . m-2 . min-1)
Study: 8544782
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin infusion (40, 80, 160 mU . m-2 . min-1)
Study: 31283555
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care (no acupuncture treatment)
Study: 25623520
Drug: Mud-bath therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud-bath therapy (12 mudpacks and 12 thermal baths) with continued TNF inhibitor treatment
Study: 25623520
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy alone (TNF inhibitors)
Study: 24964805
Drug: Quadrivalent meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent meningococcal conjugate vaccine
Study: 24964805
Drug: Quadrivalent meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent meningococcal polysaccharide vaccine
Study: 17312228
Drug: PCEA+AMB (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA+AMB (n = 21, 0.1% ropivacaine + fentanyl 2 microg/mL, bolus 5 mL, lockout 10 min, basal automated boluses of 5 mL/h)
Study: 17312228
Drug: PCEA+BCI (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA+BCI (n = 21, 0.1% ropivacaine + fentanyl 2 microg/mL, bolus 5 mL, lockout 10 min, basal infusion 5 mL/h)
Study: 15211441
Drug: n-3 Polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 Polyunsaturated fatty acids (PUFAs) 2.4 g for 8 weeks
Study: 10696320
Drug: Tropicamide 1%
Normalized name: TROPICAMIDE 1% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropicamide 1% spray
Study: 9156934
Drug: Epsilon-aminocaproic acid
Normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon-aminocaproic acid (EACA) given in a daily dose of 85-230 mg/kg for 1-11 days
Study: 26976495
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no caffeine treatment)
Study: 20222114
Drug: Ultrasound-guided corticosteroid
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided corticosteroid injection
Study: 16175189
Drug: Irinotecan (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (110 mg/m² on day 1 and 100 mg/m² on day 8) plus cisplatin (80 mg/m² on day 8)
Study: 16175189
Drug: Cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (80 mg/m² on day 1)
Study: 1417429
Drug: Imipramine hydrochloride
Normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine hydrochloride tricyclic pharmacotherapy
Study: 1417429
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy and pharmacotherapy combined
Study: 4043659
Drug: Ursodeoxycholic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid, 1000 mg/day for 1 month
Study: 27530375
Drug: Ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol mebutate gel (IMB) - 3 days treatment cycle
Study: 27530375
Drug: Daylight photodynamic
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daylight photodynamic therapy (dlPDT) - single session
Study: 23983039
Drug: TCZ‐SC (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCZ‐SC (subcutaneous tocilizumab) 162 mg every 2 weeks
Study: 23983039
Drug: TCZ‐IV (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCZ‐IV (intravenous tocilizumab) 8 mg/kg every 4 weeks
Study: 12640021
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose recombinant human IL-6 (HiIL-6; n = 6)
Study: 12640021
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose IL-6 (LoIL-6; n = 6)
Study: 10232639
Drug: Lactulose (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (25 g)
Study: 10232639
Drug: Fructooligosaccharides (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructooligosaccharides (25 g)
Study: 3121350
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg orally after 90 min of insulin infusion)
Study: 21367594
Drug: Indacaterol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 150 μg once-daily
Study: 23490225
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 μg twice-daily
Study: 19541503
Drug: Oral unsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral unsaturated fat supplements (90mL of Calogen and 4 capsules of Pikasol)
Study: 16885013
Drug: CHF3381 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF3381 (500 mg)
Study: 12131110
Drug: Gabapentin (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1,200 mg)
Study: 8154645
Drug: Cholesterol levels
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol levels lower than 4.14 mmol/L (160 mg/dL)
Study: 2680584
Drug: Theophylline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (6 mg.kg‐1)
Study: 2680584
Drug: PAF (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAF (inhaled in five successive doses every 15 min)
Study: 769707
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg D(-)penicillamine daily
Study: 769707
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg D(-)penicillamine daily
Study: 769707
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of therapy
Study: 769707
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg and 1200 mg D(-)penicillamine
Study: 29122262
Drug: Geranium aroma
Normalized name: ADENOSINE 0.012 g in 30 g TOPICAL PATCH [LOVELY GERANIUM AROMATHERAPY MASK 30g]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geranium aroma (3 drops of geranium essential oil inhaled for 20 minutes a day for 2 days)
Study: 29122262
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 drops of placebo inhaled for 20 minutes a day for 2 days)
Study: 23684411
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg once every 12 weeks
Study: 23684411
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg once every 4 weeks
Study: 12544691
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lansoprazole twice daily with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week
Study: 12544691
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rabeprazole twice daily with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week
Study: 12544691
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rabeprazole twice daily with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week
Study: 25373361
Drug: bFGF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: bFGF treatment (0.2-0.25 mL of bFGF solution applied directly onto the TM once daily until closure)
Study: 25373361
Drug: bFGF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: bFGF treatment (subgroup D, applied after 3 days post-injury)
Study: 25373361
Drug: bFGF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: bFGF treatment (subgroup C and D)
Study: 17449934
Drug: Nadroparin (7,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (7,500 U, twice daily)
Study: 17449934
Drug: Coumarin derivatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumarin derivatives with aspirin
Study: 7651639
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate therapy
Study: 7651639
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate therapy with ethinyl E2 supplementation
Study: 27916207
Drug: Insulin-supplemented medium
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-supplemented medium
Study: 23895188
Drug: Birth Preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birth Preparation Programme (BPP)
Study: 15947280
Drug: Montelukast (cysteinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (cysteinyl leukotriene antagonist)
Study: 15947280
Drug: Loratadine (antihistamine)
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine (antihistamine)
Study: 15970290
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg/day for 6 months)
Study: 2129822
Drug: Ispaghula therapy
Normalized name: ISPAGHULA
DrugBank: Plantago ovata seed (DB14585)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ispaghula therapy
Study: 28390770
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of concentrated bone marrow aspirate (cBMA) via MarrowStim
Study: 25881966
Drug: levofloxacin/bismuth therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: levofloxacin/bismuth therapy
Study: 25881966
Drug: BMT quadruple
Normalized name: BMT IM
DrugBank: Biomodulin T (DB16529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMT quadruple therapy
Study: 19482764
Drug: Light-protected parenteral
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light-protected parenteral nutrition (n = 428)
Study: 19482764
Drug: Light-exposed parenteral
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light-exposed parenteral nutrition (n = 438)
Study: 11182041
Drug: Paclitaxel (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (135 mg/m2, 3 h) and Carboplatin (AUC 4-5)
Study: 9391999
Drug: Oral trimegestone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trimegestone, 0.10 mg/day
Study: 9391999
Drug: Oral trimegestone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trimegestone, 0.25 mg/day
Study: 9391999
Drug: Oral trimegestone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trimegestone, 0.50 mg/day
Study: 9391999
Drug: Oral 17‐beta‐oestradiol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17‐beta‐oestradiol, 2 mg/day
Study: 26805433
Drug: Oral inosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inosine
Study: 20873243
Drug: Metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin alone (n=46)
Study: 20873243
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and gliclaside MB (n=47)
Study: 20873243
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and insulin (n=44)
Study: 20873243
Drug: Insulin (n=45)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin (n=45)
Study: 12477585
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine and ketamine (1 mg/mL)
Study: 10361873
Drug: Danaparoid sodium
Normalized name: Danaparoid Sodium
DrugBank: Danaparoid (DB06754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danaparoid sodium (750 anti-Xa units once daily for 8 weeks)
Study: 8572838
Drug: Enalapril maleate,
Normalized name: Enalapril Maleate, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril maleate, 10 mg/d for 5 years
Study: 7081684
Drug: Methylprednisolone 30
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 30 mg/kg administered following induction of anaesthesia and repeated with the start of cardiopulmonary bypass
Study: 31041855
Drug: Blonanserin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blonanserin (8 to 24 mg/d)
Study: 31041855
Drug: Haloperidol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (4 to 12 mg/d)
Study: 27083200
Drug: Electroacupuncture +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture + Cognitive Behavioural Therapy (EA+CBT)
Study: 24803302
Drug: AMG 181
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 181 (210 mg s.c.)
Study: 24803302
Drug: AMG 181
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 181 (various doses: 0.7, 2.1, 7, 21, 70 mg s.c. or i.v., 210 mg s.c. or i.v., 420 mg i.v.)
Study: 24803302
Drug: AMG 181
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 181 (various doses)
Study: 14635749
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose (inj. hydrocortisone 100 mg IV 6‐hourly for 3 days)
Study: 14635749
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose (inj. hydrocortisone 100 mg IV 6‐hourly on day 1, 100 mg IV 8‐hourly on day 2, and 100 mg IV 12‐hourly on day 3)
Study: 14635749
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose protocol (inj. hydrocortisone 25 mg IV 6‐hourly on day 1, 25 mg IV 8‐hourly on day 2 and 25 mg IV 12‐hourly on day 3)
Study: 11304719
Drug: r-HuEPO with
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-HuEPO with new stabilizer (glycine and Polysorbate 80) at 150 IU/kg sc dose
Study: 11304719
Drug: r-HuEPO with
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-HuEPO with new stabilizer (glycine and Polysorbate 80) at 750 IU/kg sc dose
Study: 11304719
Drug: r-HuEPO without
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-HuEPO without new stabilizer (HSA) at 150 IU/kg sc dose
Study: 11304719
Drug: r-HuEPO without
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-HuEPO without new stabilizer (HSA) at 750 IU/kg sc dose
Study: 11304719
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (with and without new stabilizer)
Study: 31492718
Drug: Ladostigil 10
Normalized name: Ladostigil
DrugBank: Ladostigil (DB16213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ladostigil 10 mg/d
Study: 29966612
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 μg, 4 times daily; n = 42)
Study: 24650820
Drug: Prescription drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription drug misuse (PDM) of one class
Study: 24650820
Drug: Prescription drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription drug misuse (PDM) of two classes
Study: 24650820
Drug: Prescription drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription drug misuse (PDM) of three classes
Study: 24650820
Drug: No prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prescription drug misuse (PDM)
Study: 16219020
Drug: Recombinant leptin
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant leptin (10 mg/morning, 10 mg/evening, or 20 mg/day)
Study: 7754943
Drug: No pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pacing therapy
Study: 3965269
Drug: Domperidone (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (acute administration)
Study: 7428183
Drug: Metoclopramide (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (acute administration)
Study: 7428183
Drug: Metoclopramide (further
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (further treatment)
Study: 7428183
Drug: Domperidone (prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (prolonged administration)
Study: 30529157
Drug: Phrenic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phrenic nerve infiltration with 10 mL of 0.25% bupivacaine
Study: 26860018
Drug: Meloxicam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (15 mg) administered orally two hours before surgery
Study: 26860018
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg) administered orally two hours before surgery
Study: 1492847
Drug: Newly developed
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly developed effervescent granules (Imbun) containing 500 mg ibuprofen lysine salt (292.6 mg ibuprofen)